Want to see IN:INDOUS full AI Analyst Report?
INDOUS Stock Chart & Stats
₹108.00
-₹4.85(-1.77%)
At close: 4:00 PM EST
₹108.00
-₹4.85(-1.77%)
Day’s Range― - ―
52-Week Range₹64.51 - ₹158.85
Previous CloseN/A
Volume1.20K
Average Volume (3M)435.00
Market Cap
₹1.36B
Enterprise Value₹2.27B
Total Cash (Recent Filing)₹5.88M
Total Debt (Recent Filing)₹276.43M
Price to Earnings (P/E)11.7
Beta1.04
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.08%
Share Statistics
EPS (TTM)3.56
Shares Outstanding20,052,000
10 Day Avg. Volume309
30 Day Avg. Volume435
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.24
Price to Sales (P/S)1.87
P/FCF Ratio-13.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp FY2026 revenue increase indicates strong demand, broader market reach, or improved product adoption across the seed business. If the company can sustain this growth through its product pipeline and distribution network, it can build greater operating scale over the next several quarters.
Equity-Supported Balance SheetA growing equity base provides a stronger capitalization foundation for research, seed production, processing, and distribution investment. Asset expansion alongside higher equity supports business capacity and gives the company more resilience than a balance sheet funded primarily through borrowing.
Integrated Seed Business And Product BreadthAn integrated seed platform can retain more value across research, production, processing, and marketing than a narrowly focused sales model. Coverage of multiple crop categories and a branded distribution network also supports customer reach and creates avenues for future product introductions.
Bears Say
Negative Operating And Free Cash FlowNegative operating and free cash flow show that reported business activity did not convert into cash during FY2026. Persistent weak conversion can restrict internally funded investment, increase reliance on financing, and reduce the company’s flexibility during seasonal working-capital demands.
Material Increase In DebtThe rise in debt increases financial risk while cash generation remains weak. More borrowing can raise repayment and refinancing pressure, limiting the funds available for research, production capacity, distribution expansion, or other initiatives needed to support the company’s growth.
Weak Earnings Conversion Despite GrowthFalling net income alongside rapid revenue growth indicates that expansion has not translated into stronger bottom-line performance. The previously thin operating profitability also raises concern that costs, pricing pressure, or operating execution could limit the durability of future revenue gains.
Indo US Bio-Tech Ltd. News
INDOUS FAQ
What was Indo US Bio-Tech Ltd.’s price range in the past 12 months?
Indo US Bio-Tech Ltd. lowest stock price was ₹64.51 and its highest was ₹158.85 in the past 12 months.
What is Indo US Bio-Tech Ltd.’s market cap?
Indo US Bio-Tech Ltd.’s market cap is ₹1.36B.
When is Indo US Bio-Tech Ltd.’s upcoming earnings report date?
Indo US Bio-Tech Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Indo US Bio-Tech Ltd.’s earnings last quarter?
Indo US Bio-Tech Ltd. released its earnings results on Aug 12, 2026. The company reported ₹1.515 earnings per share for the quarter.
Is Indo US Bio-Tech Ltd. overvalued?
According to Wall Street analysts Indo US Bio-Tech Ltd.’s price is currently Overvalued.
Does Indo US Bio-Tech Ltd. pay dividends?
Indo US Bio-Tech Ltd. pays a Notavailable dividend of ₹0.25 which represents an annual dividend yield of 0.08%. See more information on Indo US Bio-Tech Ltd. dividends here
What is Indo US Bio-Tech Ltd.’s EPS estimate?
Indo US Bio-Tech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Indo US Bio-Tech Ltd. have?
Indo US Bio-Tech Ltd. has 20,052,000 shares outstanding.
What happened to Indo US Bio-Tech Ltd.’s price movement after its last earnings report?
Indo US Bio-Tech Ltd. reported an EPS of ₹1.515 in its last earnings report. Following the earnings report the stock price went down -0.271%.
Which hedge fund is a major shareholder of Indo US Bio-Tech Ltd.?
Currently, no hedge funds are holding shares in IN:INDOUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indo US Bio-Tech Ltd.
Indo Us Bio-Tech Ltd. is an Indian firm specializing in the entire seed value chain, encompassing production, processing, packaging, and distribution across India. Their diverse product lineup features an extensive selection of vegetable seeds, including tomato, okra, bottle gourd, brinjal, carrot, cluster bean, bitter gourd, ridge gourd, cucumber, cabbage, radish, sponge gourd, various peppers (chili and sweet pepper), beetroot, cowpea, coriander, onion, watermelon, and muskmelon. The company also provides ornamental flower seeds, cotton seeds, and a variety of oilseeds such as castor, groundnut, sesame, mustard, and soybean. Furthermore, their offerings extend to spice seeds like cumin and psyllium (isabgul), pulse seeds including val, gram, black gram, and green gram, and cereal seeds such as wheat, maize, bajra, and pigeon pea. Beyond its domestic operations, Indo Us Bio-Tech Ltd. actively exports its agricultural products. The company was founded in 2004 and is headquartered in Ahmedabad, India.
Technical Analysis
Astec Lifesciences Limited
―
Best Agrolife Ltd.
―
India Pesticides Ltd.
―
Nath Bio-Genes (India) Ltd.
―
Indogulf Cropsciences Limited
―